Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Total Debt (2016 - 2023)

Marker Therapeutics (MRKR) has disclosed Total Debt for 7 consecutive years, with $97400.0 as the latest value for Q1 2023.

  • On a quarterly basis, Total Debt changed N/A to $97400.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $97400.0, a N/A change, with the full-year FY2022 number at $2.5 million, changed N/A from a year prior.
  • Total Debt was $97400.0 for Q1 2023 at Marker Therapeutics, down from $2.5 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $8.1 million in Q2 2022 to a low of $31000.0 in Q4 2019.
  • A 3-year average of $2.0 million and a median of $113200.0 in 2019 define the central range for Total Debt.
  • Biggest YoY gain for Total Debt was 625.0% in 2019; the steepest drop was 55.78% in 2019.
  • Marker Therapeutics' Total Debt stood at $31000.0 in 2019, then soared by 7964.52% to $2.5 million in 2022, then tumbled by 96.1% to $97400.0 in 2023.
  • Per Business Quant, the three most recent readings for MRKR's Total Debt are $97400.0 (Q1 2023), $2.5 million (Q4 2022), and $5.1 million (Q3 2022).